EUVIMEDEUVIMED entdecken
Crossref

In Vitro and In Vivo Metabolic Activation of Tolterodine Mediated by CYP3A

Aixuan Wang, Qiang Zhao, Minglu Liu, Yang Wang, Guode Zhao, Weiwei Li iD, Ying Peng, Jiang Zheng iD

Chemical Research in Toxicology · 2023

DOI: 10.1021/acs.chemrestox.2c00389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2023. Verfasst von Aixuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tolterodine (TOL) is an antimuscarinic drug used for the treatment of patients with overactive bladder presenting urinary frequency, urgency, and urge incontinence. During the clinical use of TOL, adverse events such as liver injury took place. The present study aimed at the investigation of the metabolic activation of TOL possibly associated with its hepatotoxicity. One GSH conjugate, two NAC conjugates, and two cysteine conjugates were found in both mouse and human liver microsomal incubations supplemented with TOL, GSH/NAC/cysteine, and NADPH. The detected conjugates suggest the production of a quinone methide intermediate. The same GSH conjugate was also observed in mouse primary hepatocytes and in the bile of rats receiving TOL. One of the urinary NAC conjugates was observed in rats administered TOL. One of the cysteine conjugates was found in a digestion mixture containing hepatic proteins from animals administered TOL. The observed protein modification was dose-dependent. CYP3A primarily catalyzes the metabolic activation of TOL. Ketoconazole (KTC) pretreatment reduced the generation of the GSH conjugate in mouse liver and cultured primary hepatocytes after TOL treatment. In addition, KTC reduced the susceptibility of primary hepatocytes to TOL cytotoxicity. The quinone methide metabolite may be involved in TOL-induced hepatotoxicity and cytotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3AChemical and Drug Induced Liver InjuryHumansRatsMiceAnimalsActivation, MetabolicTolterodine TartrateCysteineKetoconazoleMicrosomes, LiverGlutathioneIndolequinones

Substanzen

Cytochrome P-450 CYP3ATolterodine TartrateCysteineKetoconazoleGlutathionequinone methideIndolequinones

Autor:innen und Institutionen

  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China.
  • State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou 550025, P. R. China.

ORCID-Profile: Weiwei Li, Jiang Zheng

Zitieren

APA

Wang, A., Zhao, Q., Liu, M., Wang, Y., Zhao, G., Li, W., Peng, Y., & Zheng, J. (2023). In Vitro and In Vivo Metabolic Activation of Tolterodine Mediated by CYP3A. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.2c00389

Vancouver

Wang A, Zhao Q, Liu M, Wang Y, Zhao G, Li W, et al. In Vitro and In Vivo Metabolic Activation of Tolterodine Mediated by CYP3A. Chemical Research in Toxicology. 2023. doi:10.1021/acs.chemrestox.2c00389

BibTeX
@article{Wang2023,
  author = {Wang, Aixuan and Zhao, Qiang and Liu, Minglu and Wang, Yang and Zhao, Guode and Li, Weiwei and Peng, Ying and Zheng, Jiang},
  title = {In Vitro and In Vivo Metabolic Activation of Tolterodine Mediated by CYP3A},
  journal = {Chemical Research in Toxicology},
  year = {2023},
  doi = {10.1021/acs.chemrestox.2c00389}
}
Kostenlos starten →